Neuroimmunological diseases

update

研究成果: ジャーナルへの寄稿評論記事

抄録

During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.

元の言語英語
ページ(範囲)1039-1048
ページ数10
ジャーナルNippon rinsho. Japanese journal of clinical medicine
66
発行部数6
出版物ステータス出版済み - 1 1 2008

Fingerprint

Molecular Targeted Therapy
Multiple Sclerosis
Integrin alpha4beta1
Myasthenia Gravis
Opportunistic Infections
Autoimmune Diseases
Disease Progression
Monoclonal Antibodies
Recurrence
Antibodies
Pharmaceutical Preparations
Therapeutics
Natalizumab
alemtuzumab

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Neuroimmunological diseases : update. / Kira, Jun-Ichi.

:: Nippon rinsho. Japanese journal of clinical medicine, 巻 66, 番号 6, 01.01.2008, p. 1039-1048.

研究成果: ジャーナルへの寄稿評論記事

@article{89f96bff38ba4e77899f9dffdd319e33,
title = "Neuroimmunological diseases: update",
abstract = "During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barr{\'e} syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.",
author = "Jun-Ichi Kira",
year = "2008",
month = "1",
day = "1",
language = "English",
volume = "66",
pages = "1039--1048",
journal = "Nippon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "6",

}

TY - JOUR

T1 - Neuroimmunological diseases

T2 - update

AU - Kira, Jun-Ichi

PY - 2008/1/1

Y1 - 2008/1/1

N2 - During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.

AB - During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.

UR - http://www.scopus.com/inward/record.url?scp=48049093969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049093969&partnerID=8YFLogxK

M3 - Review article

VL - 66

SP - 1039

EP - 1048

JO - Nippon rinsho. Japanese journal of clinical medicine

JF - Nippon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 6

ER -